Safety Considerations and Future Outlook As with all pharmacotherapy for obesity and T2D, establishing cardiovascular safety and demonstrating improvements in meaningful clinical outcomes will be essential, particularly as cardiovascular outcome trials have not yet been completed with multi-agonists (although data are expected soon for tirzepatide: SURPASS-CVOT [T2D] in 2025
Limitations Article heterogenicity There are several limitations of this review, most of which are due to the nature of the articles included
"At base level, however, the molecules are similar and subserve identical bodily functions appetite suppression and the promotion of insulin secretion from the pancreas." For more Health articles, visit www.foxnews/health The most common side effects of liraglutides include nausea, vomiting , diarrhea, decreased appetite, indigestion and constipation, according to the companys release
Saxenda specifically activates GLP-1 receptors with high affinity, which is why it produces measurable metabolic effects
You might feel it on your arms, legs, back, face, or anywhere on your body, and the affected areas can shift
To measure the effect of GLP-1R in CM, a selective GLP-1R agonist (liraglutide) and an antagonist (exendin(939)) were applied in the experiment
)
